SCHEMBL10308261

SCHEMBL10308261

CCCn1ccc(C(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.33
RAB9A P51151 6/20 0.33
HTT P42858 5/20 0.33
LMNA P02545 3/20 0.33
APOBEC3A P31941 2/20 0.33
APOBEC3G Q9HC16 2/20 0.33
ALDH1A1 P00352 1/20 0.33
PABPC1 P11940 1/20 0.33
POLB P06746 3/20 0.32
GALR3 O60755 2/20 0.32
ATM Q13315 2/20 0.32
MAPK1 P28482 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HSP90AA1 P07900 1/20 0.32
MAPT P10636 1/20 0.32
RAD52 P43351 1/20 0.32
PAX8 Q06710 1/20 0.32
NR2F2 P24468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2737269 0.83 HTT (0.30) HTT
SCHEMBL25744924 0.77 PDE2A (0.30)
SCHEMBL20780318 0.77 TSHR (0.31) SMN1; SMN2
SCHEMBL25648822 0.73
SCHEMBL28861739 0.73 NPC1 (0.41) NPC1RAB9AHTTLMNAAPOBEC3A
SCHEMBL25463633 0.72 NPC1 (0.32) NPC1RAB9AHTTLMNAAPOBEC3A
SCHEMBL23920431 0.71 SIGMAR1 (0.49) NPC1RAB9AHTTALDH1A1SMN1; SMN2
SCHEMBL26972547 0.71 RAF1 (0.35) NPC1RAB9AHTTLMNAAPOBEC3A
SCHEMBL12016980 0.71 PTPN5 (0.30)
SCHEMBL1126620 0.71 AKR1B1 (0.54) NPC1RAB9ALMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-20230242514-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-08-03 US disclosed
US-20120178780-A1 RAF KINASE INHIBITORS WOOD JILL E (US) 2012-07-12 US disclosed
US-20100063088-A1 Raf Kinase Inhibitors WOOD JILL E 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists NR3C1, NR3C2, MC2R NPC1 1457/4885RAB9A 3949/4885HTT 4598/4885
US-20100063088-A1 Raf Kinase Inhibitors BRAF, RAF1, ARAF NPC1 2990/4885RAB9A 1819/4885HTT 4540/4885
US-20230242514-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, NR1I2 NPC1 1893/4885RAB9A 4839/4885HTT 4102/4885
US-20120178780-A1 RAF KINASE INHIBITORS BRAF, RAF1, ARAF NPC1 2990/4885RAB9A 1819/4885HTT 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.